Senator Orrin Hatch, R-Utah, has filed an amendment to the Creating and Restoring Equal Access to Equivalent Samples Act, which was advanced to the Senate by the Judiciary Committee on June 14, 2018.
Senator Orrin Hatch, R-Utah, has filed an amendment to the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act), which was advanced to the Senate by the Judiciary Committee on June 14, 2018.
The amendment, S.974 #EHF18270, which Hatch has titled the “Hatch-Waxman Integrity Act of 2018,” would prevent generic and biosimilar drug applicants from availing themselves of both standard litigation procedures (provided for under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act [BPCIA]) and inter partes review (IPR) or post-grant review (PGR) proceedings in seeking to invalidate patents held by innovator product sponsors.
The proposed amendment would require that a generic drug applicant certify that it has not filed—nor does it plan to file—a petition to institute an IPR or PGR for a patent covering the innovator drug; in essence, if a generic developer hopes to use the abbreviated Hatch-Waxman pathway to approval, it must promise not to utilize the IPR or PGR process. The amendment makes a similar provision for biosimilars; if a biosimilar developer plans to use the BPCIA approval pathway for its product, it must certify that it has not filed, and will not file, a petition to institute an IPR or PGR.
Finally, the proposal seeks to prevent the “manipulative and deceptive use” of IPRs by restricting anyone from engaging in a short sale of a publicly traded security held by a patent owner during a 90-day period before or after that individual or affiliate petitions for an IPR proceeding on that patent.
According to Hatch’s remarks prepared for the Judiciary Committee, “My amendment would preserve Hatch-Waxman as the standard path for generic companies to challenge brand patents, while keeping IPR as an option in situations where other interests come into play.” He added that the legislation “would prevent companies from using IPR to put added litigation pressure on innovators above and beyond what Hatch-Waxman already provides. And it would prevent a company that rightfully loses a Hatch-Waxman suit from getting a second bite at the apple.”
The IPR process, recently upheld by the Supreme Court of the United States after challenges to the constitutionality of the process, has become an integral part of the patent challenge landscape in the biosimilar and generic context given that IPR may be faster and less costly than the standard litigation process.
The Association for Accessible Medicines (AAM), which represents generic and biosimilar drug developers and has been a vocal supporter of the CREATES Act, told The Center for Biosimilars® in an email that it is recommending that lawmakers vote no on Hatch’s amendment; “IPR and Hatch-Waxman patent litigation serve [2] different but equally vital functions, and Congress intended to make both systems available,” said AAM, adding that “Eliminating invalid patents by brand name drug companies is necessary to permit patient access to more affordable generic and biosimilar medicines. Generics are a proven solution to high drug prices and policies that continue to foster generic access are needed. The IPR process is just one of those policies.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.